TNBC, TRIPLE NEGATIVE BREAST CANCER

This Phase II trial will test whether adding a live biotherapeutic product called MO-03 (a type of probiotic) to standard chemotherapy and the immunotherapy drug pembrolizumab can improve outcomes for 50 people with early-stage triple-negative breast cancer. Participants will tak…

This phase 2 trial tests whether adding a targeted drug (axatilimab) and radiation to the immunotherapy pembrolizumab can help shrink tumors in people with metastatic triple-negative breast cancer who have already tried immunotherapy. About 34 participants will receive all three …

This study tests a combination of two drugs, inavolisib and eribulin, in people with advanced triple-negative breast cancer that has a PIK3CA mutation and has not responded to at least one prior treatment. The goal is to see if the combination shrinks tumors and is safe. About 26…

This phase 2 study is testing fluzoparib, a daily pill, as a maintenance therapy for people with advanced triple-negative breast cancer whose disease was controlled by platinum chemotherapy. The trial will enroll 72 participants with or without BRCA gene mutations. The goal is to…

This phase II trial is testing whether a combination of two drugs—sacituzumab govitecan (a targeted chemotherapy) and tislelizumab (an immunotherapy)—can effectively treat early-stage triple-negative breast cancer with a less intense approach. The study will enroll 30 people and …

This Phase 2 trial tests whether adding the immunotherapy drug toripalimab to chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. About 216 participants will receive either toripalimab plus one of two chemotherapy regimens. The main goa…

This phase 2 trial tests a combination of two drugs—Sacituzumab Tirumotecan and Toripalimab—as a first treatment for people with a specific type of advanced triple-negative breast cancer that is PD-L1 positive. The study aims to see if the combo shrinks tumors and improves surviv…

This study tests a new drug called SC-101 in 120 people with advanced breast cancer (triple-negative or hormone-receptor-positive) that has a specific gene change called NECTIN4 amplification. Participants receive the drug once a week through an IV. The goal is to see if the drug…

This early-phase study tests a new imaging agent that targets a protein called TROP2, found on many cancer cells. About 40 adults with metastatic bladder, breast, or lung cancer will receive the agent to see where it goes in the body. The goal is to see if this tracer can help do…

This study looks back at data from 201 people with triple-negative breast cancer who received chemotherapy or immunotherapy before surgery. The goal is to compare how often the cancer completely disappears after treatment and find out what factors influence success. This is an ob…